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Abstract
Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease caused by homozygous inactivation of the SMN1
gene and reduced levels of the survival motor neuron (SMN) protein. Since higher copy numbers of the nearly identical
SMN2 gene reduce disease severity, to date most efforts to develop a therapy for SMA have focused on enhancing SMN
expression. Identification of alternative therapeutic approaches has partly been hindered by limited knowledge of potential
targets and the lack of cell-based screening assays that serve as readouts of SMN function. Here, we established a cell
system in which proliferation of cultured mouse fibroblasts is dependent on functional SMN produced from the SMN2 gene.
To do so, we introduced the entire human SMN2 gene into NIH3T3 cell lines in which regulated knockdown of endogenous
mouse Smn severely decreases cell proliferation. We found that low SMN2 copy number has modest effects on the cell
proliferation phenotype induced by Smn depletion, while high SMN2 copy number is strongly protective. Additionally, cell
proliferation correlates with the level of SMN activity in small nuclear ribonucleoprotein assembly. Following miniaturization
into a high-throughput format, our cell-based phenotypic assay accurately measures the beneficial effects of both
pharmacological and genetic treatments leading to SMN upregulation. This cell model provides a novel platform for
phenotypic screening of modifiers of SMN2 gene expression and function that act through multiple mechanisms, and a
powerful new tool for studies of SMN biology and SMA therapeutic development.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
neurodegenerative disease characterized by loss of motor neurons
in the anterior horn of the spinal cord and skeletal muscle atrophy
[1]. SMA is caused by reduced levels of the survival motor neuron
(SMN) protein, an evolutionarily conserved and ubiquitously
expressed protein essential for viability [2,3]. SMN exists in a
macromolecular complex with functions in the assembly of the
small nuclear ribonucleoproteins (snRNPs) of the RNA splicing
machinery and possibly other RNA-protein complexes [4–6]. In
animal models of SMA, the disruption of snRNP biogenesis
induced by SMN deficiency decreases snRNP levels [7–9] and
causes splicing defects in genes that contribute to motor system
dysfunction [10–12].
The human genome contains two genes that code for the SMN
protein, SMN1 and SMN2, with multiple copies of SMN2 present
[13]. SMA patients have homozygous loss or mutations of the
SMN1 gene and retention of at least one copy of SMN2. Although
the two SMN genes are nearly identical, a C to T transition in exon
7 of SMN2 disrupts splicing regulatory elements resulting mainly in
the production of transcripts lacking exon 7 (SMND7) with only a
small proportion encoding full-length SMN [14–17]. SMN2 exon
7 skipping creates a destabilizing element responsible for the rapid
degradation of the SMND7 protein [18–20]. As a consequence,
reduced levels of full-length SMN protein produced from the
SMN2 gene, while sufficient to prevent embryonic lethality, are not
able to fully compensate for the loss of SMN1 resulting in motor
neuron disease.
There is a direct connection between SMN protein levels and
SMA severity as higher SMN2 gene copy number correlates with
milder forms of the disease in patients [21–23]. Thus, most efforts
in developing SMA therapeutics have focused on methods to
increase SMN protein levels. These include activation of the
SMN2 promoter, enhancing inclusion of exon 7 in SMN2-derived
transcripts, increasing the stability of SMN mRNA and protein, or
restoring SMN expression through gene therapy [24–27]. In
agreement with the viability of these approaches, injection of AAV
vectors encoding full-length SMN in mouse models of SMA
resulted in remarkable correction of lifespan and motor function
[28–31]. Similarly, robust phenotypic benefit in SMA mice was
accomplished by promoting SMN2 exon 7 inclusion using
antisense oligonucleotides targeting intronic splicing silencers
[32,33]. Small chemical compounds that increase SMN expression
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e71965
are also being investigated for SMA therapy. The use of histone
deacetylase (HDAC) inhibitors has been shown to result in
phenotypic improvement in SMA mice through SMN2 transcrip-
tional upregulation [34,35]. Additional inducers of SMN expres-
sion have been identified in high-throughput chemical screens
[36–40]. C5-substituted quinazolines [37], the most clinically
advanced therapeutic candidates emerged from these screens,
potently inhibit the activity of the scavenger decapping enzyme
DcpS [41] and improve survival and motor phenotype in SMA
mice [42–44]. Although these candidate therapeutics are now
entering clinical trials, SMA remains the most frequent genetic
cause of infant mortality worldwide for which no effective
treatment is currently available.
Ongoing efforts to address the high unmet clinical need in SMA
would benefit from increased knowledge of basic SMN biology
and disease mechanisms as well as identification of alternative
therapeutic approaches. In addition to upregulation of SMN
expression, strategies aiming to enhance SMN function or to
correct downstream effects of SMN deficiency might provide new
avenues for SMA therapy. Accordingly, there is evidence that
SMN function is regulated both in vivo and in vitro [45,46] and that
targeting downstream defects induced by SMN deficiency without
increasing SMN levels can be beneficial in animal models of SMA
[10,11,47–50]. However, progress towards the development of
alternative therapeutic strategies for SMA has generally been
hindered by lack of suitable targets as well as screening platforms
that supply readouts of SMN function and downstream SMN-
dependent events. In an effort to address this shortcoming, we
developed a novel cell-based system for phenotypic screening of
chemical or genetic modifiers that may increase SMN expression
and function through multiple mechanisms of action. To do so, we
have taken advantage of a previously characterized mouse
NIH3T3 cell line in which regulated knockdown of endogenous
mouse Smn triggers a severe cell proliferation defect [11],
providing a direct phenotypic readout of SMN function. We
introduced the human SMN2 gene into this cell line, generating a
system where cell proliferation is sensitive to changes in functional
SMN levels produced from SMN2. We further miniaturized and
validated a cell-based phenotypic assay in 96-well format
amenable to high-throughput chemical and genetic screens. Our
cell model system provides a novel tool for the discovery of cellular
factors and genetic networks that control SMN biology in
mammalian cells, which will not only increase our knowledge of
the basic biology of SMN but also contribute to SMA therapeutic
development.
Results
Development of Human SMN2-containing NIH3T3 Cell
Lines with Regulated Knockdown of Endogenous Smn
We recently established and characterized an NIH3T3-
SmnRNAi cell line with drug-inducible, RNAi-mediated knock-
down of endogenous mouse Smn [11,12]. In these cells, addition
of doxycycline causes Smn depletion and subsequent, severe cell
proliferation defects that can be corrected by transgenic expression
of RNAi-resistant human SMN [11]. We sought to modify this
model system so that cell proliferation would be dependent on
SMN levels produced by the human SMN2 gene. To do so, the
35.5 kb BamHI fragment corresponding to the genomic region
encompassing the SMN2 gene (Figure 1A), previously used to
generate SMA mice [51], was cloned into a cosmid vector
containing a neomycin selection cassette under the control of the
SV40 promoter and the resulting construct was transfected into
NIH3T3-SmnRNAi cells. Several neomycin-resistant stable cell
lines were isolated through antibiotic selection and cloning by
limiting dilution in 96-well plates. Here, we describe the
characterization of two representative NIH3T3-SMN2/SmnRNAi
cell lines with either low or high SMN2 copy number. Genomic
DNA from these NIH3T3 cell lines was isolated and the relative
SMN2 gene copy number was determined by quantitative PCR
with human SMN-specific primers. NIH3T3-SMN2high/SmnRNAi
cells contained more than tenfold the number of SMN2 copies
present in NIH3T3-SMN2low/SmnRNAi cells (Figure 1B). Consis-
tent with this, RT-qPCR analysis with human-specific SMN
primers showed that in the absence of doxycycline NIH3T3-
SMN2high/SmnRNAi cells expressed approximately ten times the
amount of total SMN2 mRNA compared to NIH3T3-SMN2low/
SMNRNAi cells (Figure 1C). Importantly, radioactive RT-PCR
analysis revealed the expected pattern of exon 7 splicing regulation
of the SMN2 gene in both cell lines (Figure 1D). Irrespective of the
marked difference in the overall levels SMN2 expression, the
majority of SMN2 transcripts lacked exon 7 (SMND7) and only
,10% were full-length SMN mRNA.
Next, we investigated the expression and subcellular localization
of the human SMN protein in NIH3T3-SMN2/SmnRNAi cells. In
agreement with the SMN2 gene copy number and mRNA
expression levels, Western blot analysis with an antibody that
specifically detects human SMN revealed that in the absence of
doxycycline NIH3T3-SMN2high/SmnRNAi cells express approxi-
mately tenfold more SMN than NIH3T3-SMN2low/SmnRNAi cells
(Figure 2). Human SMN protein was not detected in either wild-
type or NIH3T3-SmnRNAi cells that do not contain the SMN2
gene, confirming the specificity of the antibodies. We then carried
out immunofluorescence experiments with a human SMN-specific
antibody (anti-hSMN) or an antibody that recognizes both mouse
and human SMN proteins (anti-SMN) in NIH3T3 cell lines
cultured without doxycycline. Analysis in NIH3T3-SmnRNAi cells
showed no staining with anti-hSMN but strong cytoplasmic and
weak nuclear staining with anti-SMN (Figure 3A and 3D). As
expected, staining with anti-hSMN was weak in NIH3T3-
SMN2low/SmnRNAi cells (Figure 3B) and strong in NIH3T3-
SMN2high/SmnRNAi cells (Figure 3C), and revealed a similar
subcellular distribution to that of endogenous mouse Smn.
Noticeably, SMN localization in nuclear foci known as Gems
[52] while rare in wild-type NIH3T3 cells was frequently observed
in NIH3T3-SMN2high/SmnRNAi cells, possibly due to higher
SMN levels.
Lastly, we investigated whether the capacity for doxycycline-
inducible, RNAi-mediated knockdown of endogenous Smn
characteristic of parental NIH3T3-SmnRNAi cells was retained in
the newly established NIH3T3-SMN2/SmnRNAi cell lines. We
first analyzed the effects of doxycycline on the expression levels of
mouse Smn mRNA by RT-qPCR. As expected [11], doxycycline-
treated NIH3T3-SmnRNAi cells had strongly decreased levels of
Smn mRNA compared to untreated cells and doxycycline had no
effects in wild-type NIH3T3 cells (Figure 4A). Doxycycline caused
a reduction in Smn mRNA levels in both NIH3T3-SMN2low/
SmnRNAi and NIH3T3-SMN2high/SmnRNAi cells similar to that in
NIH3T3-SmnRNAi cells, demonstrating that these cells preserved
the ability for inducible knockdown of Smn mRNA. Consistent
with the shRNA specific targeting of mouse Smn mRNA, human
SMN2 mRNA levels were unaffected by RNAi induction with
doxycycline in NIH3T3-SMN2/SmnRNAi cells (Figure 4B). We
then carried out Western Blot analysis to determine the levels of
SMN protein expression following knockdown of endogenous
Smn. In agreement with Smn mRNA levels and our previous
studies [11,12], doxycycline treatment of NIH3T3-SmnRNAi cells
for 7 days strongly reduced SMN protein levels to approximately
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10% of normal, but had no effect in wild-type NIH3T3 cells
(Figure 4C). Importantly, the amounts of SMN in doxycycline-
treated NIH3T3-SMN2low/SmnRNAi (,20%) and NIH3T3-
SMN2high/SmnRNAi cells (,80%) relative to untreated cells were
consistent with the levels of human SMN mRNA expressed from
the SMN2 gene. Thus, we developed NIH3T3 cell lines with
regulated knockdown of endogenous Smn that express either low
or high levels of human SMN from the SMN2 gene.
Cell Proliferation Correlates with SMN2 Gene Expression
and Function in Smn-deficient NIH3T3-SMN2/SmnRNAi
Cells
SMN deficiency elicits a severe cell proliferation phenotype in
NIH3T3 cells [11]. Smn-deficient NIH3T3-SmnRNAi cells display
decreased proliferation after 3 days of doxycycline treatment and
become growth arrested at day 5, entering a quiescent proliferative
state that could last for many days without significant cell death
[11]. While doxycycline has no effect in wild-type NIH3T3 cells,
transgenic expression of human SMN is able to correct cell
proliferation defects in Smn-deficient NIH3T3 cells [11], indicat-
ing that the effects are specifically due to SMN depletion. We
therefore investigated the effect of SMN2 gene expression on cell
proliferation in NIH3T3-SMN2/SmnRNAi cell lines cultured in
the presence or absence of doxycycline for 7 days (Figure 5A). Smn
deficiency resulted into a twenty-fold difference in the number of
NIH3T3-SmnRNAi cells relative to wild-type NIH3T3 cells, in
Figure 1. Development of SMN2-containing NIH3T3 cell lines with inducible knockdown of endogenous Smn. (A) Schematic
representation of the exon-intron structure of the human SMN2 gene used to establish NIH3T3-SMN2/SmnRNAi cell lines (introns not drawn to scale).
(B) Analysis of SMN2 gene copy number in the indicated NIH3T3 cell lines by qPCR. Data were normalized to the Gapdh gene and expressed relative
to the NIH3T3-SMN2low/SmnRNAi cell line. Data are represented as mean and SEM (n= 3; ** = p,0.01; t-test). (C) Analysis of total SMN2 mRNA levels in
the indicated NIH3T3 cell lines by RT-qPCR. Data were normalized to Gapdh mRNA and expressed relative to the NIH3T3-SMN2low/SmnRNAi cell line.
Data are represented as mean and SEM (n= 3; *** = p,0.001, t-test). (D) Analysis of SMN2 exon 7 splicing in the indicated NIH3T3 cell lines by
radioactive RT-PCR. The levels of exon 7 inclusion are shown at the bottom.
doi:10.1371/journal.pone.0071965.g001
Figure 2. Analysis of human SMN protein levels in NIH3T3-
SMN2/SmnRNAi cell lines. Western blot of equal amounts of proteins
from wild-type (Control), NIH3T3-SmnRNAi, NIH3T3-SMN2low/SmnRNAi
and NIH3T3-SMN2high/SmnRNAi cell lines with monoclonal antibodies
against the indicated proteins. Monoclonal antibodies specific to
human SMN (hSMN) or both mouse and human SMN (SMN) were
used. A two-fold serial dilution of the extract from NIH3T3-SMN2high/
SmnRNAi cells is shown on the right.
doi:10.1371/journal.pone.0071965.g002
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which doxycycline had no effect on proliferation. Consistent with
the expression of low levels of human SMN from the SMN2 gene,
NIH3T3-SMN2low/SMNRNAi cells exhibited a strong cell prolif-
eration defect following knockdown of endogenous Smn, but this
effect was significantly less severe than that in NIH3T3-SmnRNAi
cells. In particular, despite very slow cell proliferation, Smn-
deficient NIH3T3-SMN2low/SmnRNAi cells unlike NIH3T3-
SmnRNAi cells did not stop growing even after prolonged culture
in the presence of doxycycline. Increased levels of human SMN
expression from the SMN2 gene in NIH3T3-SMN2high/SmnRNAi
cells resulted in a robust albeit incomplete correction of the cell
proliferation phenotype triggered by Smn deficiency, with
NIH3T3-SMN2high/SmnRNAi cells on average cycling ,10%
more slowly than wild-type NIH3T3 cells in the presence of
doxycycline. These results indicated that proliferation of Smn-
deficient NIH3T3-SMN2/SmnRNAi cells is proportional to the
levels of human SMN expressed from the SMN2 gene.
Next, we investigated SMN function and its correlation with
proliferation in NIH3T3-SMN2/SmnRNAi cell lines. The only
molecularly defined activity of SMN is in the assembly of the Sm
core on spliceosomal snRNAs [53,54] and the degree of reduction
in snRNP assembly correlates with disease severity in mouse
models of SMA [7]. We previously showed that snRNP assembly is
severely decreased in Smn-deficient NIH3T3-SmnRNAi cells and
restored by expression of human SMN, while doxycycline has no
effect [11]. We carried out in vitro snRNP assembly experiments
using radioactive U1 snRNA and extracts from NIH3T3 cell lines
cultured with or without doxycycline followed by immunoprecip-
itation with anti-SmB antibodies to monitor Sm core formation
in vitro. These experiments showed that the SMN-dependent
snRNP assembly defects are slightly (two-fold) less severe in
NIH3T3-SMN2low/SmnRNAi cells compared to NIH3T3-
SmnRNAi cells that do not contain the SMN2 gene and significantly
rescued in NIH3T3-SMN2high/SmnRNAi cells (Figure 5B). Over-
all, these data demonstrated that SMN expression from the SMN2
gene correlates well with snRNP assembly activity and cell
proliferation in our model system.
Development of a Cell-based Phenotypic Assay for SMN-
dependent Cell Proliferation in NIH3T3 Cells
We sought to develop a cell-based assay for high-throughput
chemical and genetic screens of modifiers of SMN expression and
function that uses reduced proliferation as a robust phenotypic
readout of SMN deficiency in NIH3T3 cells. First, we developed
an automated, imaging-based approach to determine cell number
in 96-well format as a measure of SMN-dependent cell prolifer-
ation in NIH3T3 cells. Serial dilutions of NIH3T3-SMN2low/
SmnRNAi cells were seeded in a 96-well optical plate, followed by
fixation and nuclear staining with Hoechst 4 hours later. Direct
determination of cell number was then carried out by whole well
imaging with an IN Cell Analyzer. These experiments demon-
strated a linear relationship between the number of cells plated
and the optical readout of Hoechst-stained nuclei (Figure 6A).
Thus, in addition to being rapid and cost-effective, this method-
ology showed remarkable linearity over a wide range of cell
number.
Next, we investigated whether SMN-dependent effects on cell
proliferation in NIH3T3 cells could be assessed using a 96-well
format and the above readout. To do so, NIH3T3-SmnRNAi and
NIH3T3-SMN2low/SmnRNAi cells were cultured with and without
doxycycline for 5 days prior to seeding 200 cells into 6 replicate
wells of a 96-well plate, with doxycycline treatment continuing
throughout the course of the experiment. Cell number was
determined at 4 hours (time zero) as well as 4 and 5 days post-
plating using Hoechst staining followed by imaging with the IN
Cell Analyzer. Figure 6B shows representative whole well images
of normal and SMN-deficient NIH3T3-SMN2low/SmnRNAi cells
at 5 days post-plating in 96-well plates. These experiments
Figure 3. Subcellular localization of the human SMN protein in NIH3T3-SMN2/SmnRNAi cell lines. Indirect immunofluorescence and
confocal microscopy analysis of NIH3T3-SmnRNAi (A and D), NIH3T3-SMN2low/SmnRNAi (B and E) and NIH3T3-SMN2high/SmnRNAi (C and F) cell lines
using monoclonal antibodies specific to human SMN (hSMN, panels A–C) or both mouse and human SMN (SMN, panels D–F). Scale bar, 10 mm.
doi:10.1371/journal.pone.0071965.g003
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revealed a similar time-dependent increase in the number of
untreated NIH3T3-SmnRNAi and NIH3T3-SMN2low/SmnRNAi
cells with normal levels of SMN and the time zero analysis
confirmed the presence of equal numbers of cells at plating
(Figure 6C-D). Consistent with the growth arrest phenotype at the
time of plating, the number of doxycycline-treated NIH3T3-
SmnRNAi cells did not change over time (Figure 6C). In contrast,
doxycycline-treated NIH3T3-SMN2low/SmnRNAi showed a mod-
Figure 4. Inducible knockdown of endogenous mouse Smn in NIH3T3-SMN2/SmnRNAi cell lines. (A) RT-qPCR analysis of mouse Smn
mRNA levels in wild-type (Control), NIH3T3-SmnRNAi, NIH3T3-SMN2low/SmnRNAi and NIH3T3-SMN2high/SmnRNAi cell lines cultured with and without
Dox for 7 days. Data in Dox-treated cells were normalized to those in untreated cells and represented as mean and SEM (n = 3; *** =p,0.001; t-test).
(B) RT-qPCR analysis of human SMN2 mRNA levels in NIH3T3-SMN2low/SmnRNAi and NIH3T3-SMN2high/SmnRNAi cell lines cultured with and without
Dox for 7 days. Data in Dox-treated cells were normalized to those in untreated cells and represented as mean and SEM. (C) Western blot analysis of
equal amounts of proteins from wild-type (Control), NIH3T3-SmnRNAi, NIH3T3-SMN2low/SmnRNAi and NIH3T3-SMN2high/SmnRNAi cell lines cultured with
and without Dox for 7 days using monoclonal antibodies against the indicated proteins. For each cell line, SMN levels in Dox-treated relative to
untreated cells are shown at the bottom.
doi:10.1371/journal.pone.0071965.g004
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est time-dependent increase in cell number (Figure 6D), consistent
with both a much slower rate of proliferation relative to untreated
cells and the differential severity of the phenotype triggered by
Smn deficiency in NIH3T3-SMN2low/SmnRNAi compared to
NIH3T3-SmnRNAi cells (see also Figure 5). The largest difference
in cell number between normal and Smn-deficient cells was
observed at 5 days post-plating for both NIH3T3-SmnRNAi (,40-
fold) and NIH3T3-SMN2low/SmnRNAi (,5-fold) cells. Thus, we
established a cell-based phenotypic assay in 96-well format that
accurately measures SMN-dependent effects on proliferation of
NIH3T3 cells.
Genetic and Pharmacological Modulation of SMN-
dependent Cell Proliferation in NIH3T3 Cells
Next we determined whether the cell proliferation defects
caused by SMN deficiency in NIH3T3 cells could be modulated
by genetic and chemical approaches. First, we investigated the
capacity for the system to respond to genetic approaches by
assessing the ability of lentiviral-mediated human SMN expression
to correct the cell proliferation phenotype in Smn-deficient
NIH3T3 cells using our 96-well format assay. Both NIH3T3-
SmnRNAi and NIH3T3-SMN2low/SmnRNAi cells in which Smn
deficiency was induced by preincubation with doxycycline for 5
days were plated in 6 replicate wells of 96-well plates in the
presence of doxycycline as well as increasing amounts of lentivirus
expressing human SMN driven by the CMV promoter. The
number of vehicle- and lentivirus-treated NIH3T3 cells was
determined 5 days later using Hoechst nuclear staining and IN
Cell Analyzer imaging. These experiments revealed that human
SMN expression promoted cell proliferation of Smn-deficient
NIH3T3 cells in a dose-dependent manner with a maximum
increase in cell number of 3.5-fold for NIH3T3-SmnRNAi cells and
nearly 3-fold for NIH3T3-SMN2low/SmnRNAi cells compared to
their corresponding vehicle-treated controls (Figure 7). With the
amount of lentivirus that most effectively promotes cell prolifer-
ation, the level of human SMN expressed is equivalent to
endogenous mouse Smn in wild-type NIH3T3 cells (data not
shown). Furthermore, lentiviral-mediated expression of GFP under
the same conditions had no effect on the proliferation of Smn-
deficient NIH3T3 cells (data not shown), confirming the specificity
for the effects of SMN restoration.
We also tested whether SMN-dependent cell proliferation could
be modulated by treatment with small chemical compounds. We
used the histone deacetylase inhibitor valproic acid (VPA), which
was previously demonstrated to increase SMN levels in human
SMA fibroblasts [55,56], leading to improved motor function and
survival in a mouse model of SMA [57]. We performed dose-
response analysis of VPA effects on cell proliferation of doxycy-
cline-treated NIH3T3-SMN2low/SmnRNAi and NIH3T3-
SmnRNAi cells using the same conditions employed in lentiviral
transduction experiments. We found that VPA treatment resulted
in dose-dependent stimulation of cell proliferation in Smn-
Figure 5. Effect of human SMN2 expression on proliferation and snRNP assembly in Smn-deficient NIH3T3 cell lines. (A) Analysis of
cell proliferation in wild-type (Control), NIH3T3-SmnRNAi, NIH3T3-SMN2low/SmnRNAi and NIH3T3-SMN2high/SmnRNAi cell lines cultured with and without
doxycycline for 7 days. For each cell line, the cell number ratio of Dox-treated cells versus untreated cells is expressed relative to that of wild-type
cells, which is set to 1. Data are represented as mean and SEM (n$3; *** = p,0.001; one-way ANOVA). (B) Analysis of U1 snRNP assembly in NIH3T3
cell lines. In vitro snRNP assembly experiments were carried out with radioactive U1 snRNA and extracts from wild-type NIH3T3 (Control), NIH3T3-
SmnRNAi, NIH3T3-SMN2low/SmnRNAi and SMN2high/SmnRNAi cells cultured with and without doxycycline for 7 days. For each cell line, the amounts of
immunoprecipitated U1 snRNA were quantified and the RNA ratio in Dox-treated cells versus untreated cells is expressed relative to that of wild-type
cells, which is set to 1. Data are represented as mean and SEM (n$3; * = p,0.05; ** = p,0.01; *** = p,0.001; one-way ANOVA).
doi:10.1371/journal.pone.0071965.g005
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deficient NIH3T3-SMN2low/SmnRNAi cells compared to vehicle-
treated controls (Figure 8A). There was a maximum 2.5-fold
increase in cell number at 1 mM, while higher drug concentra-
tions appeared toxic. Importantly, VPA treatment had no effect on
the proliferation of Smn-deficient NIH3T3-SmnRNAi cells lacking
the SMN2 gene (Figure 8A). The specificity of the effects for
NIH3T3-SMN2low/SmnRNAi cell lines containing the SMN2 gene
was consistent with the predicted mechanism of action for VPA in
increasing SMN2 gene expression. To determine whether this was
indeed the case, we compared SMN mRNA and protein levels in
Smn-deficient NIH3T3-SMN2low/SmnRNAi and NIH3T3-
SmnRNAi cells treated with 1 mM VPA relative to vehicle-treated
controls. RT-qPCR experiments showed that VPA treatment did
not change the low level of Smn mRNA in either NIH3T3-
SMN2low/SmnRNAi or NIH3T3-SmnRNAi cells (Figure 8B–C),
indicating that it did not interfere with the doxycycline-dependent
RNAi knockdown of endogenous mouse Smn. In contrast, VPA
treatment resulted in a ,1.5-fold increase in total SMN mRNA
produced from the SMN2 gene in NIH3T3-SMN2low/SmnRNAi
cells compared to vehicle-treated cells (Figure 8C). A similar
increase was also found for full-length SMN mRNA (data not
shown). In agreement with the observed changes in mRNA levels,
Western blot analysis showed that the low Smn protein levels were
unaffected by VPA in Smn-deficient NIH3T3-SmnRNAi cells
(Figure 8D), while VPA treatment increased SMN protein levels
(1.7-fold, p,0.01) in NIH3T3-SMN2low/SmnRNAi cells compared
Figure 6. An SMN-dependent cell proliferation assay in 96-well format. (A) Automated determination of NIH3T3 cell number in 96-well
format. Two-fold serial dilutions of NIH3T3-SMN2low/SMNRNAi cells were plated in eight replicate wells of a 96-well plate. Following fixation and
Hoechst staining 4 hours later, cell number was determined by imaging whole wells with an IN Cell Analyzer 2000. (B) Representative IN Cell Analyzer
images of NIH3T3-SmnRNAi cells cultured with or without Dox in a 96-well format. (C–D) Analysis of SMN-dependent cell proliferation in NIH3T3-
SmnRNAi (C) and NIH3T3-SMN2low/SmnRNAi (D) cells using the 96-well format assay. NIH3T3 cells were cultured for 5 days with or without Dox, and
then seeded in six replicate wells of a 96-well plate. Dox-treatment was continued throughout the experiment. Cell number was determined at 4
hours (T0), 4 days and 5 days post-plating. Data are represented as mean and SEM (n= 6; *** =p,0.001; two-way ANOVA).
doi:10.1371/journal.pone.0071965.g006
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to vehicle-treated cells (Figure 8E). These results were consistent
with the beneficial effects of VPA on proliferation of NIH3T3-
SMN2low/SmnRNAi cells being the consequence of SMN upregu-
lation. The observation that moderate SMN induction with VPA
elicits an effect on cell proliferation of NIH3T3-SMN2low/
SmnRNAi cells similar to that of complete, lentiviral-mediated
SMN restoration can be explained by differences in the timing of
SMN expression. Characteristic of the lentiviral system, there is a
lag of approximately one day between viral transduction and the
onset of transgenic SMN expression, which delays the biological
effect of SMN restoration. In contrast, small molecules such as
VPA can readily engage their cellular targets and act more
quickly. It is therefore possible, if not likely that some chemical
compounds could have a more robust effect than we observe with
the SMN lentivirus in our cell proliferation assay.
Collectively, these experiments provided proof of concept that
cell proliferation defects induced by Smn deficiency could be
improved by genetic or pharmacological upregulation of SMN in
NIH3T3-SMN2low/SmnRNAi cells and thus used as a phenotypic
readout in future screens for modifiers of SMN2 gene expression or
function.
Discussion
SMA is a devastating neurological disease for which no effective
treatment is currently available. Progress in the discovery of new
SMA therapeutic approaches has been hampered, at least in part,
by the relatively limited knowledge of targets and the lack of assays
in high-throughput format that provide a functional readout of
SMN activity. To facilitate the identification of novel targets and
therapeutics that act not only on SMN expression but also on
SMN function and downstream events induced by SMN
deficiency, we developed a cell-based system that uses cell
proliferation defects triggered by SMN deficiency in cultured
mammalian cells as phenotypic readout of the functional levels of
SMN produced from the SMN2 gene. Following miniaturization of
this cell-based assay for use in high-throughput format, we provide
proof of principle for the application of this novel platform for
unbiased, genetic and chemical screens that aim to identify and
characterize modifiers of SMN expression and function that act
through any one of multiple, possible mechanisms of action. Thus,
our work establishes a powerful new discovery tool for the study of
SMN biology and possibly the development of novel approaches
for SMA therapy.
SMN is an essential gene that is required for cell growth and
viability from yeast to mammals [11,58–62]. The model system we
developed is based on a mouse NIH3T3 fibroblast cell line
(NIH3T3-SmnRNAi) in which regulated knockdown of endogenous
mouse Smn triggers a severe cell proliferation defect [11],
providing a direct phenotypic readout of SMN function. The
rationale of the work was to adapt this system for purposes of
therapeutic and biological discovery in SMA research by
introducing the entire human SMN2 gene into NIH3T3-SmnRNAi
cells, thereby making cell proliferation dependent on the levels of
functional SMN produced from the SMN2 gene. We successfully
isolated NIH3T3 cell lines with either low or high SMN2 copy
numbers and demonstrated that cell proliferation is proportional
to the levels of human SMN expression following RNAi depletion
of endogenous Smn. Consistent with the phenotypic effects of
varying SMN2 copy numbers in mice lacking the Smn alleles
[51,63], we found that low SMN2 copy number modestly improves
the proliferation phenotype of Smn-deficient NIH3T3 cells, while
Figure 7. Genetic modulation of SMN-dependent proliferation in NIH3T3 cells. Dose-response analysis of lentiviral-mediated human SMN
expression on cell proliferation of SMN-deficient NIH3T3-SmnRNAi and NIH3T3-SMN2low/SmnRNAi cells. In these experiments, NIH3T3 cells were
cultured for 5 days with Dox prior to seeding in six replicate wells of a 96-well plate in the presence of Dox. Vehicle or increasing amounts of SMN-
expressing lentivirus were added 4 hours later. For each group and treatment, cell number was determined at 5 days post-plating and normalized to
that of the corresponding vehicle-treated cells. Data are represented as mean and SEM (n = 6; * = p,0.05; ** = p,0.01; *** = p,0.001; one-way
ANOVA).
doi:10.1371/journal.pone.0071965.g007
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high SMN2 copy number is remarkably protective. In animal
models of SMA, snRNP assembly defects correlate with disease
severity [7] and restoration of snRNP levels coincides with
phenotypic correction [8,64]. Similarly, we show a direct
correlation between the degree of SMN-dependent snRNP
assembly impairment and the severity of the cell proliferation
phenotype in our model system. Moreover, functional analysis of
several SMN point mutations associated with SMA revealed that
their ability to support snRNP assembly and correct the
proliferation defects in Smn-deficient NIH3T3 fibroblasts is
proportional to their potency in rescuing motor neuron pheno-
types in animal models and inversely correlated with clinical
severity in patients (L. Pellizzoni, C. Beattie and A. Burghes,
unpublished results). Lastly, reduced cell proliferation induced by
SMN deficiency in select brain regions has been associated with
impaired perinatal brain development in severe SMA mice [65].
Altogether, this evidence supports the conclusion that the effect of
SMN deficiency on cell proliferation in this system mirrors at least
some of the mechanisms at play in the disease.
As the copy number of the nearly identical SMN2 gene
correlates with disease severity [21–23], SMA therapeutic
development has primarily focused on enhancing the expression
of full-length SMN from the SMN2 gene or through gene therapy
[24–27]. To date, cell-based screens for SMA therapeutic
discovery have employed reporter assays that monitor increased
SMN2 transcription and exon 7 splicing [36–39]. Immunodetec-
tion and imaging methodologies were also used to screen for small
molecules that upregulate SMN protein levels in human SMA
fibroblasts [40]. However, cell-based phenotypic assays that
measure increased SMN expression and function from the
SMN2 gene and are amenable to high-throughput screening have
not been developed. Thus, our cell system has a number of distinct
benefits, which complement and significantly advance currently
available tools for SMA translational research, affording the
opportunity to identify cellular factors and genetic networks linked
to SMN biology in a comprehensive and mechanistically unbiased
manner. First, the presence of the entire SMN2 gene allows for the
identification of potential modifiers acting at any level of SMN
gene expression from transcription to protein turnover. Second,
our platform is able to capture the possible beneficial effects of
modifiers that act not only on SMN expression but also on its
activity as well as downstream SMN-dependent pathways. Lastly,
comparison of the effects of candidate chemical and genetic
modifiers on the proliferation of SMN-deficient NIH3T3-
SmnRNAi and NIH3T3-SMN2/SmnRNAi cell lines will provide
the opportunity for effective hit deconvolution and rapid
identification of modifiers acting through SMN2-dependent and
-independent mechanisms for priority ranking and early mecha-
nistic insights.
The robust cell proliferation phenotype of NIH3T3-SMN2/
SmnRNAi cells combined with the development of an assay in 96-
well format provides the foundation for the applicability of our
platform to high-throughput screening. Additionally, direct
measure of NIH3T3 cell number by a single-step method
comprising nuclear Hoescht staining followed by automated
imaging is a rapid, cost-effective and accurate method for assessing
SMN-dependent cell proliferation in the 96-well format. In
support of the conclusion that our phenotypic platform is suitable
for screening modifiers of SMN biology, we provide proof-of-
concept that it can respond to either genetic or pharmacological
intervention. We show that lentiviral-mediated SMN transduction
promotes proliferation of both NIH3T3-SMN2/SmnRNAi and
NIH3T3-SmnRNAi cells in a dose-dependent and SMN2-indepen-
dent manner, highlighting the specificity and reversibility of the
phenotype induced by Smn deficiency. Conversely, consistent with
SMN2 gene upregulation and the results of previous studies
[55,56], we show that the beneficial effects of treatment with the
HDAC inhibitor VPA on cell proliferation are restricted to Smn-
deficient NIH3T3-cells containing SMN2. Together, these features
support the viability of our system for use in high-throughput
chemical and genetic screening projects for SMA discovery.
In conclusion, the cell system for phenotypic screening we
developed provides a powerful new tool for identifying and
validating modifiers of SMN expression and function, which
promise to yield not only critical insights into our understanding of
the basic biology of SMN but also new therapeutic avenues for the
treatment of SMA.
Materials and Methods
NIH3T3 Cell Lines and Tissue Culture
The NIH3T3 cell line with inducible knockdown of endogenous
mouse Smn (NIH3T3-SmnRNAi) used in this study has been
described previously [11,12]. To generate human SMN2-contain-
ing NIH3T3 cell lines with regulated Smn knockdown, the 35.5 kb
BamHI fragment corresponding to the human genomic region
encompassing the SMN2 gene, previously used to generate SMA
transgenic mice [51], was excised from a BAC construct (a gift
from Dr. Arthur Burghes) and cloned into the SuperCos1 cosmid
vector (Stratagene). The resulting vector was transfected into
NIH3T3-SmnRNAi cells and stable NIH3T3-SMN2/SmnRNAi
cells were isolated through antibiotic selection with G418
(0.5 mg/ml). Clonal cell lines were obtained by limiting dilution
in 96-well plates.
NIH3T3 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) with high glucose (Gibco) containing 10% fetal
bovine serum (HyClone), 2 mM glutamine (Gibco), and 0.1 mg/
ml gentamicin (Gibco). Smn RNAi was induced by addition of
doxycycline (Fisher) to the growth medium at a final concentration
of 100 ng/ml as previously described [11,12].
Lentiviral constructs expressing GFP and SMN driven by the
CMV promoter were generated by standard cloning techniques
using the pRRLSIN.cPPT.PGK-GFP.WPRE vector (Addgene
plasmid 12252) as a backbone [66,67]. For lentivirus production,
viral stocks pseudotyped with the vesicular stomatitis G protein
(VSV-G) were prepared by transient co-transfection of 293 T cells
Figure 8. Pharmacological modulation of SMN-dependent proliferation in NIH3T3 cells. (A) Dose-response analysis of VPA treatment on
cell proliferation of SMN-deficient NIH3T3-SmnRNAi and NIH3T3-SMN2low/SmnRNAi cells. In these experiments, NIH3T3 cells were cultured for 5 days
with Dox prior to seeding in six replicate wells of a 96-well plate in the presence of Dox. Vehicle or increasing amounts of VPA were added 4 hours
later. For each group and treatment, cell number was determined at 5 days post-plating and normalized to that of the corresponding vehicle-treated
cells. Data are represented as mean and SEM (n= 6; * = p,0.05; ** = p,0.01; *** = p,0.001; one-way ANOVA). (B–C) RT-qPCR analysis of mouse Smn
and human SMN2 mRNA levels in NIH3T3-SmnRNAi (B) and NIH3T3-SMN2low/SmnRNAi (C) cells cultured with Dox for 3 days and then in the presence of
either water (Vehicle) or 1 mM VPA for additional 4 days. Data from triplicate RT-qPCR experiments normalized to Gapdh mRNA are represented as
mean and SEM (** = p,0.01; t-test). (D–E) Western blot analysis of SMN protein levels in NIH3T3-SmnRNAi (D) and NIH3T3-SMN2low/SmnRNAi (E) cells
cultured with Dox for 3 days and then in the presence of water (Vehicle) or 1 mM VPA for additional 4 days. Blots were probed with an antibody that
recognizes both mouse and human SMN proteins. SMN levels in VPA-treated relative to vehicle-treated cells are shown at the bottom.
doi:10.1371/journal.pone.0071965.g008
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as previously described [11]. Lentiviral particles in supernatants
were harvested, concentrated by ultracentrifugation for 2 hours
and 30 minutes at 19,500 rpm in a SW28 rotor (Beckman), and
titered using the Lenti-XTM qRT-PCR Titration Kit (Clontech).
DNA and RNA Analysis
For genomic DNA analysis, cells were washed twice in ice cold
PBS and harvested into 500 ml of PK buffer (10 mM EDTA,
100 mM Tris-HCl, pH 7.5, 300 mM NaCl, 2% SDS) containing
1 mg/ml proteinase K followed by overnight incubation at 50uC
with shaking at 800 rpm. After addition of 500 ml of isopropanol
and further incubation for 2 hours at room temperature, genomic
DNA was pulled out of solution and resuspended in TE buffer
(10 mM Tris-HCl, 1 mM EDTA pH 7.5).
Total RNA from NIH3T3 cells was isolated using Trizol
reagent (Invitrogen) followed by digestion with DNase I (Ambion).
RNA (1 mg) was reverse transcribed using RevertAid First Strand
cDNA Kit (Fermentas). For analysis of SMN2 exon 7 splicing,
semi-quantitative RT-PCR reactions were carried out in the
presence of a forward primer 59 end-labeled using T4 polynucle-
otide kinase (New England BioLabs) and [32P]-ATP (Perkin
Elmer) as previously described [12]. PCR products were amplified
using AmpliTaq Gold DNA polymerase (Roche), resolved on an
8% polyacrylamide-8 M urea gel, and subjected to autoradiogra-
phy. The linear range of PCR amplication was determined
independently for each experiment. Quantification of radiolabeled
PCR products was carried out using a Typhoon PhosphorImager
(Molecular Dynamics). For quantitative RT-qPCR experiments,
triplicate reactions were carried out using Power SYBR Green
PCR master mix (Applied Biosystem) in a Realplex4 Mastercycler
(Eppendorf). RT-qPCR data were normalized to Gapdh mRNA.
The primers utilized in this study were previously reported [12].
Antibodies
The following antibodies were used in this study: anti-SMN
clone 8 (BD Transduction Laboratories), anti-SMN 7F3 [68], anti-
SmB 18F6 [69], anti-human SMN (a gift from Dr. Adrian
Krainer), and anti-Tubulin DM 1A (Sigma).
Western Blot Analysis
Analysis was performed as described previously [12]. In short,
proteins were fractionated by SDS/PAGE on 12% polyacrylamide
gels and transferred onto a Trans-Blot transfer medium nitrocel-
lulose membrane (Bio-Rad) using 1X Tris-glycine buffer (Bio-Rad)
containing 20% methanol. The blots were blocked in 5% nonfat
dry milk in PBS containing 0.1% Tween 20 for 1 h at room
temperature. Membranes were washed 3 times for 10 minutes with
PBS containing 0.1% Tween 20 at room temperature. Incubation
with secondary antibodies conjugated to horseradish peroxidase
was performed in PBS containing 0.1% Tween 20 for 1 h at room
temperature. Chemiluminescence was carried out using a Super-
signal West Pico Chemilumiescent substrate according to the
supplier’s recommendations (Thermo Scientific). SMN protein
levels were quantified after normalization to Tubulin using
ImageJ.
Immunofluorescence Analysis
NIH3T3 cells were grown on glass coverslips in 24-well plates.
Cells were washed once with PBS and then fixed in 4%
paraformaldehyde-PBS for 15 minutes at room temperature.
Following fixation, cells were permeabilized in 0.5% Triton-X in
PBS for 5 minutes at room temperature. Blocking and both
primary and secondary antibody incubations were performed with
3% BSA in PBS. Images were collected with a SP5 confocal
microscope (Leica).
In vitro snRNP Assembly
In vitro snRNP assembly experiments were performed using
radioactive U1 snRNA and NIH3T3 cell extracts (25 mg) followed
by immunoprecipitation with anti-SmB antibodies, electrophoresis
on denaturing polyacrylamide gels and autoradiography as
previously described [7,11]. Quantification of immunoprecipitated
U1 snRNA was carried out using a Typhoon PhosphorImager
(Molecular Dynamics).
Cell Proliferation Assay in 96-well Format
NIH3T3 cells were cultured with or without doxycycline for 5
days prior to seeding in 96-well format. NIH3T3 cells were
counted with an automatic digital cell counter (ADAM, Digital
Bio) and dispensed in 96-well optical plates (Grainer) at 200 cells
per well in 200 ml of media continuing the prior treatment with or
without doxycycline. Vehicle and serial dilutions of valproic acid
or lentiviral particles were added 4 hours post-plating (six replicate
wells for each concentration) and NIH3T3 cells further incubated
for different times in culture. For determination of cell number, a
4X solution containing 16% paraformaldehyde and 8mg/ml of
Hoechst in PBS was added to each well of the 96-well plate and
incubated for 15 minutes at room temperature. After washing with
PBS, whole-well imaging acquisition was performed with the IN
Cell Analyzer 2000 (GE Healthcare) followed by nuclear counting
with the IN Cell Investigator (GE Healthcare) software.
Statistical Analysis
Statistical analysis was carried out with the Prism 5 (GraphPad)
software using two-tailed unpaired Student’s t-test and one-way or
two-way ANOVA followed by the Bonferroni post-hoc test as
indicated. Data are represented as mean plus SEM and P values
are indicated as follows: * = p,0.05; ** = p,0.01; *** = p,0.001.
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